Canadian Researchers Honoured for Advances in Thrombosis & Equitable Cancer Research

TORONTO, ON – November 20, 2025 – The Health Research Foundation (HRF) today announced Dr. Jeffrey Weitz as the recipient of the 2025 HRF Medal of Honour and Dr. Juliet Daniel as the recipient of the 2025 HRF Diversity & Equity in Research Award, recognizing their significant contributions to health research and dedication to advancing equitable healthcare practices.

Pioneering Thrombosis Research Earns Top Honour

Dr. Jeffrey Weitz, a Distinguished University Professor at McMaster University, has been awarded the prestigious HRF Medal of Honour for his decades of groundbreaking work in the prevention and treatment of thrombosis. His research has fundamentally reshaped our understanding of blood clotting disorders and paved the way for life-saving anticoagulant therapies. “Dr. Weitz’s contributions have had a profound impact on patient care worldwide,” noted a leading cardiologist familiar with his work. “His research didn't just improve treatments; it changed the entire standard of care.”

Dr. Weitz’s work laid the scientific foundation for novel direct oral anticoagulants (DOACs) like apixaban and rivaroxaban, offering patients a safer and more effective alternative to traditional blood thinners. These medications have dramatically reduced the risk of stroke and blood clots, improving outcomes for millions globally. The impact of his research extends beyond the laboratory, influencing clinical guidelines and shaping best practices in thrombosis management. His work is evidenced by an extensive publication record, with over 115,000 citations to his research.

The HRF Medal of Honour, awarded annually since 1945, recognizes individuals who have made exceptional contributions to the field of health research, demonstrating sustained leadership and innovation. The award underscores the importance of Canadian researchers in driving medical breakthroughs and improving the lives of patients.

Addressing Equity in Cancer Research with Groundbreaking Insights

Dr. Juliet Daniel, also a Distinguished University Professor at McMaster University, has been awarded the HRF Diversity & Equity in Research Award for her pivotal work in cancer biology and her unwavering commitment to inclusivity in healthcare. Her research focuses on the Kaiso gene, a critical factor in the development of aggressive cancers, particularly triple-negative breast cancer (TNBC).

TNBC is a particularly challenging form of breast cancer, often diagnosed at a later stage and with a poorer prognosis. Dr. Daniel’s research has revealed the crucial role of the Kaiso gene in the spread of TNBC, opening new avenues for targeted therapies. Significantly, her work has highlighted the disproportionate impact of TNBC on young Black women, bringing critical attention to racial disparities in cancer outcomes. “Dr. Daniel’s research isn't just scientifically rigorous; it’s deeply impactful from a social justice perspective,” said one health equity advocate. “She's tackling both the biology of cancer and the systemic factors that contribute to health inequities.”

Beyond her laboratory research, Dr. Daniel is a dedicated advocate for equity, diversity, and inclusion in the scientific community. She co-founded the Canadian Black Scientists Network, a vital organization supporting and mentoring Black scholars in STEM fields. Her commitment extends to actively promoting inclusive research practices, ensuring that diverse populations are represented in clinical trials and benefit from advancements in healthcare.

The HRF Diversity & Equity in Research Award, now in its third year, recognizes researchers who are championing inclusive practices and addressing systemic barriers in health research. The award emphasizes the importance of ensuring that all communities benefit from advancements in healthcare, regardless of their background or identity.

A Growing Commitment to Inclusive Research Funding

The Health Research Foundation’s recognition of both Dr. Weitz and Dr. Daniel underscores a growing commitment to funding research that is both scientifically rigorous and socially impactful. The Foundation, affiliated with Innovative Medicines Canada (IMC), plays a critical role in supporting Canadian health research and fostering innovation. While IMC member companies collectively invest over $3.2 billion annually in research and development, the HRF focuses on strategic investments that address pressing healthcare challenges and promote health equity.

The HRF's Diversity & Equity Award, in particular, reflects a deliberate effort to address systemic inequities in research funding and ensure that diverse voices are represented in the scientific community. This is a vital step toward creating a more inclusive and equitable healthcare system for all Canadians. The impact of past award winners, such as Dr. Oluwabukola Salami and Dr. Sonia Anand, demonstrates the tangible benefits of prioritizing diversity and equity in research funding. “The HRF is showing real leadership in this area,” noted an industry observer. “They’re not just talking about diversity; they’re putting their money where their mouth is.”

The recognition of these two distinguished researchers highlights the critical importance of supporting innovative research and fostering a more inclusive and equitable scientific community, ultimately improving the health and well-being of all Canadians.